Research Reports

Prepared Highlights

Total revenue: Q4 2025 $281.3M (+39% YoY); full year 2025 $982.0M (+33% YoY) (prepared)
Oncology revenue: Q4 $189.9M (+30% YoY); full year $683.6M (+26% YoY) (prepared)
Oncology volumes: Q4 ~79,000 tests (+38% YoY); full year ~276,000 tests (+34% YoY) (prepared)
Guardant360 liquid volumes: Q4 nearly +30% YoY; full year +25% YoY (prepared)
Reveal: fastest-growing oncology product; benefited from CRC surveillance Medicare coverage (prepared)
Screening (Shield) revenue: Q4 $35.1M (~38,000 tests); full year $79.7M (~87,000 tests) (prepared)
Shield ASP: ~$850 in Q4; ADLT rate $1,495 secured through December 2027 (prepared)
Biopharma & data revenue: Q4 $54.0M (+9% YoY); full year $210.1M (+18% YoY) (prepared)
Non-GAAP gross margin: Q4 66% (vs 63% prior year); full year 66% (vs 62% in 2024) (prepared)
Shield non-GAAP gross margin: improved to 52% in Q4; cost per test ~$450 at year-end (prepared)
Adjusted EBITDA loss: Q4 $64.9M (improved from $78.4M prior year); full year $220.9M (vs $257.5M in 2024) (prepared)
Free cash flow burn: full year 2025 $233M (improved $42M YoY); core business (ex-screening) FCF positive in Q3 and Q4 (prepared)
Cash: ~$1.3B at year-end after MetaSight acquisition ($59M upfront) and financing (prepared)
RPO/backlog: not stated

Official Guidance (Full Year 2026)

Total revenue: $1.25B–$1.28B (+27%–30% YoY) (CFO)
Oncology revenue growth: 25%–27% YoY; volume growth ~30% (CFO)
Screening revenue: $162M–$174M; 210,000–225,000 Shield tests (CFO)
Biopharma & data: low double-digit revenue growth (CFO)
Non-GAAP gross margin: 64%–65% (CFO)
Non-GAAP operating expenses: $1.03B–$1.05B (+14%–16% YoY) (CFO)
Free cash flow burn: $185M–$195M; core business (ex-screening) FCF positive for full year (CFO)

Mgmt Quotes

"2025 was a breakout year for Guardant, where years of investment continues to fuel breakthrough innovation and best-in-class execution across our portfolio." (Helmy Eltoukhy, Co-CEO)
"We believe Shield is the most successful diagnostic launch in history outside of COVID testing and is positioned to be a significant multiyear growth driver for Guardant." (AmirAli Talasaz, Co-CEO)
"We are uniquely positioned with scaled offerings spanning both treatment selection and monitoring, enabling a more comprehensive view of the patient journey." (Helmy Eltoukhy, Co-CEO)
"We expect the core business to be free cash flow positive for the full year 2026 and remain committed to achieving company-wide cash flow breakeven by the end of 2027." (Michael Bell, CFO)
"We are excited to announce collaborations with Quest Diagnostics and PA Group, which will broaden our national reach in 2026." (AmirAli Talasaz, Co-CEO)

Prepared Metrics

Metric	Value	Speaker/Context
Total Revenue (Q4 2025)	$281.3M (+39% YoY)	Prepared
Total Revenue (FY 2025)	$982.0M (+33% YoY)	Prepared
Oncology Revenue (Q4)	$189.9M (+30% YoY)	Prepared
Oncology Tests (Q4)	~79,000 (+38% YoY)	Prepared
Guardant360 Liquid ASP	$3,000–$3,100	CFO
Guardant360 Tissue ASP	~$2,000	CFO
Reveal ASP	$600–$700	CFO
Shield Revenue (Q4)	$35.1M (~38,000 tests)	Prepared
Shield ASP	~$850	CFO
Shield Cost per Test (Q4 exit)	~$450	CFO
Biopharma & Data Revenue (Q4)	$54.0M (+9% YoY)	Prepared
Non-GAAP Gross Margin (Q4)	66%	Prepared
Non-GAAP Gross Margin (FY)	66%	Prepared
Shield Non-GAAP Gross Margin (Q4)	52%	CFO
Adjusted EBITDA Loss (Q4)	$64.9M	Prepared
Adjusted EBITDA Loss (FY)	$220.9M	Prepared
Free Cash Flow Burn (FY 2025)	$233M	Prepared
Cash (Year-End 2025)	~$1.3B	CFO
Shield Real-World Adherence	93%	AmirAli Talasaz
Shield Sales Reps (Year-End 2025)	~300	AmirAli Talasaz
Shield ADLT Rate	$1,495 (secured through Dec 2027)	AmirAli Talasaz
MetaSight Acquisition Upfront	$59M	CFO
MetaSight Contingent Consideration	Up to $90M	CFO

Q&A Batch (1-5 of 14)

Q1 — Daniel Leonard

Topic: Reveal 治疗监测的机遇及其与 Guardant360 的协同效应
Key points:
- Reveal 治疗监测可与 Guardant360 协同，在患者治疗进展后桥接至下一次 Guardant360 检测。
- 当获得 IO 监测和化疗监测的报销许可后，这可能成为未来几年肿瘤业务的重要增长动力。
Mgmt stance: 看涨，因为 Reveal 与 360 的协同作用及潜在的报销进展将驱动增长。

Q2 — Puneet Souda

Topic: 2026 年肿瘤业务各产品（G360、Reveal、组织检测）的增长预期
Key points:
- 预计 Guardant360 在 2026 年将再次实现强劲增长，临床检测量增长至少 20%。
- Reveal 将继续是增长最快的产品，并预计在治疗监测的推动下进一步加速。
- Guardant360 组织检测在 2025 年下半年加速，预计 2026 年将继续加速，FDA 批准 Guardant360 可能带来拉动效应。
Mgmt stance: 看涨，所有肿瘤产品均有望实现强劲增长，符合 2028 年长期规划目标。

Q3 — Douglas Schenkel

Topic: Shield 筛查业务的现金消耗、2026 年销售代表招聘节奏及公司整体自由现金流
Key points:
- 2025 年公司总现金消耗为 2.33 亿美元，其中筛查业务消耗约 2.2 亿美元。
- 预计 2026 年筛查业务的现金消耗水平与 2025 年相似，约为 2.2 亿美元。
- 2026 年全公司自由现金流指引为消耗 1.85 亿至 1.95 亿美元，意味着剔除筛查后的业务将产生约 3000 万美元的正现金流。
- 2026 年将继续投资建设商业团队，将增量毛利润再投资于销售和营销基础设施。
Mgmt stance: 中性偏乐观，对管理现金消耗有信心，但 2026 年仍是筛查业务的投资年，预计 2027 年迎来拐点。

Q4 — Tycho Peterson

Topic: ADLT 定价进展、肿瘤业务指引的保守性及 Shield 平均售价 (ASP) 预期
Key points:
- Guardant360 的 ADLT 定价申请有望在 2026 年下半年完成，但未纳入 2026 年指引。
- 2026 年肿瘤业务临床检测量增长指引为 30%，管理层认为该指引已非常强劲。
- Shield 的 ASP 预计将因 65 岁以下（商业保险）人群需求增长导致的支付方组合变化而下降。
- Shield 的 ADLT 费率 1495 美元在 2026 和 2027 年保持不变，国际业务在 2026 年的贡献预计仍然较小。
Mgmt stance: 中性，指引中未包含多项潜在利好，但 ASP 面临支付方组合变化带来的下行压力。

Q5 — Daniel Markowitz

Topic: Reveal Ultra 的差异化特性、竞争格局及更新时间表
Key points:
- Reveal Ultra 按计划将于今年推出，管理层相信其临床灵敏度将达到同类最佳。
- 该检测将具备超越其他肿瘤知情型产品的更多功能。
- 更多细节将在今年晚些时候分享。
Mgmt stance: 看涨，认为 Reveal Ultra 将重新定义肿瘤知情型检测的灵敏度标准。

Q&A Batch (6-10 of 14)

Q6 — Andrew Brackmann

Topic: MCED legislation impact on Shield
Key points:
- Passage of MCED legislation is "encouraged" but "not a meaningful driver" of near-term business.
- Potential opportunity for Shield if triannual testing becomes relevant in midterm.
- No near-term business plan change based on this legislation.
Mgmt stance: Neutral — acknowledges field progress but downplays immediate revenue impact.

Q7 — Subhalaxmi Nambi

Topic: MCED Shield opt-in rate and FDA submission path
Key points:
- Provider and patient opt-in enthusiasm is "encouraging"; opt-in rate is "trending up" but exact number not disclosed.
- Company expects to have "widest, broadest clinical data" on MCED utility in U.S. patient population in near future.
- No commitment on FDA submission timeline for RSE approval.
Mgmt stance: Bullish — excited about data accumulation and adoption, but avoids specific milestones.

Q8 — Unknown Analyst (Aaron for Mike)

Topic: Shield volume guidance, seasonality, and Quest/PathGroup tailwinds
Key points:
- 2026 guide midpoint: 217,000 Shield volumes (from 87,000 in 2025); revenue growth expected.
- Q1 seasonality in PCP offices is "normal"; guidance is "thoughtful" and not based on one quarter.
- ACS guideline update not included in guide; Quest/PathGroup co-promotion volume contribution is "very minor" and not counted in guide.
- EMR connectivity benefit from Quest/PathGroup is included, but sales rep volume impact will be monitored before adjusting guidance.
Mgmt stance: Neutral — optimistic about trends but conservative in guidance, waiting for data before raising expectations.

Q9 — Mark Massaro

Topic: Shield DTC spending and Quest sales incentives
Key points:
- DTC pilot conducted in select markets in 2025; 2026 will see more active campaigns (digital and potentially TV).
- Quest salespeople are incentivized (part of commission plan) to promote Shield.
- Quest management views Shield as a "differentiated brand" to engage accounts.
Mgmt stance: Bullish — excited about DTC expansion and Quest partnership, but monitoring actual impact.

Q10 — Kyle Mikson

Topic: MetaSight acquisition — noncancer launch path and technology fit
Key points:
- Most consideration tied to future commercial performance and regulatory approval.
- MetaSight brings "complementary technologies" (mass spec) to Guardant’s NGS-heavy Smart Platform.
- No details on noncancer launch path or integration timeline; described as "small technology tuck-in."
Mgmt stance: Neutral — excited but non-committal, deferring details to later.

Q&A Batch (11-14 of 14)

Q11 — Casey Woodring

Topic: Shield Q1 季节性及 ACS 指南更新对量的潜在影响
Key points:
- 管理层确认 Q1 存在 PCP 办公室的季节性影响，但团队通过重新安排预约，有望使 Q1 筛查患者数超过上市后任一往季。
- 约十几个州有州级强制令，要求更年轻的患者群体获得检测机会；整个筛查市场中约 40% 为 65 岁及以上人群，更年轻人群占比更大。
- ACS 指南更新若落地，可能成为商业检测在相关州深入拓展的显著增长驱动因素，但具体时间待定。
Mgmt stance: 中性偏乐观，因 Q1 有望创筛查量新高，且 ACS 指南更新可能带来额外上行空间，但需等待实际落地。

Q12 — Paul Stewardson

Topic: 竞争对手 MCED 试验未达主要终点及 FDA 灵活性的影响
Key points:
- 管理层认为多癌种早检领域的关键在于早期阶段检测性能，并相信 Shield 技术在此方面具有潜力。
- 公司正利用 Shield 的商业化规模，大规模收集接受 MCED 检测患者的临床证据和医疗记录，以建立效用证据。
- 管理层认为该路径在运营支出上友好且速度快。
Mgmt stance: 更加乐观，因竞争对手的结果凸显了公司通过商业化规模收集真实世界证据这一策略的优势。

Q13 — Luke Sergott

Topic: Shield 需求来源（护理缺口闭合 vs. 竞品份额获取）
Key points:
- 需求来自 PCP 医生，患者类型仍集中于未筛查人群；约 90% 接受 Shield 筛查的患者在过去至少 5 年内未曾接受过筛查。
- 护理缺口相关机会尚未成为增长驱动力，因 Shield 尚未获得 HEDIS 等质量评分资格。
- 一旦获得 HEDIS 资格，预计将成为巨大的额外增长驱动因素。
Mgmt stance: 乐观，因当前增长主要来自扩大整体筛查率，且护理缺口项目代表未来的增量机会。

Q14 — Jack Meehan

Topic: 肿瘤业务销售团队投资及 NovaSeq X 过渡带来的成本节约
Key points:
- 肿瘤业务去年已实现现金流为正，今年将继续产生现金；公司会根据每位销售代表收入增长情况，持续再投资以扩张团队。
- Guardant360 向 NovaSeq X 的全面过渡预计在年中左右完成。
- 目前 Guardant360 毛利率处于 60% 高位，全面过渡完成后，预计毛利率将提升约 200 个基点，推至 70% 出头的水平。
Mgmt stance: 乐观，因肿瘤业务处于健康状态，且 NovaSeq X 过渡将对损益表产生积极影响。